Home › Studies › PRJEB97162
PRJEB97162 ERP179753

FMT phageome engraftment in recurrent C. difficile, Switzerland

Engraftment of donor phageome via fecal microbiota transplantation in recurrent C. difficile infection

39 samples from donor and recipients in Switzerland, studying phage community engraftment following fecal microbiota transplantation (FMT) for recurrent C. difficile infection, in an intervention design. machine-written summary

39 samples · 39 runs · CH · Adult · 2025 · 1.42 Gbp / sample

Sources
✓Sequence archive 516✓Abstract / description 78–Full text–Supplementary tables–External resources–User contribution–Human verified

Checked this project's papers and archive records yourself? Mark it human-verified.

what each source gave
✓ Sequence archive516 sample values (age, bmi, collection date, country, diet, diet detail, intervention, intervention detail)
✓ Abstract / description78 sample values (health condition, health condition detail)
– Full textno open-access full text linked
– Supplementary tablesno supplementary tables available (or none open access)
– External resourcesnot covered by the external resources we ingest
– User contributionnothing uploaded yet
– Human verifiednot yet checked by a person · I checked this project — verify it
Interventions

intervention · arms resolved

before · no interventionbefore · no interventi33 samplesFMTFMT6 samples
single arm: samples before and on the intervention

3 people have samples in more than one arm.

Faecal microbiota transplantation design single_arm_before_after · population gi_infection_or_diarrhoea · FMT capsules for recurrent C. difficile infection

“engraftment in patients receiving FMT to treat rCDi” — bioproject.description (study level; per-sample arms are in the intervention column below)

Samples at a glance
1 sampling locations · 1 country
Age
adult36
elderly3
Condition
gi_infection_or_diarrhoea39
Sex
male33
female6
Country
CH39
Body site
primary39
Collected 2021–2024
2021: 12 samples2023: 18 samples2024: 9 samples20212024
Sequencing depth per sample · this project all projects
all projects, 0–0.03 Gbp: 25,080 samples (4 %)this project, 0–0.03 Gbp: 1 samplesall projects, 0.03–0.1 Gbp: 17,066 samples (3 %)this project, 0.03–0.1 Gbp: 2 samplesall projects, 0.1–0.3 Gbp: 29,179 samples (5 %)this project, 0.1–0.3 Gbp: 4 samplesall projects, 0.3–1 Gbp: 47,044 samples (8 %)this project, 0.3–1 Gbp: 4 samplesall projects, 1–3 Gbp: 124,983 samples (22 %)this project, 1–3 Gbp: 22 samplesall projects, 3–10 Gbp: 253,728 samples (44 %)this project, 3–10 Gbp: 6 samplesall projects, 10–30 Gbp: 72,533 samples (13 %)all projects, 30–100 Gbp: 3,024 samples (1 %)all projects, 100–300 Gbp: 106 samples (0 %)all projects, ≥ 300 Gbp: 9 samples (0 %)project median 1.42 Gbp per sample0130Gbp
Sampling design and relatedness

longitudinalFMT donor → recipient

5 of 5 people sampled more than once (39 samples; median 3, up to 18 per person) · follow-up median 58 d (max 2 mo) · median interval between samples 7 d (time from collection dates). Schedule stated by the source: “Recipients sampled before FMT (d0), and at 14 and 60 days post-FMT” (time origin: fmt); stated follow-up 2 mo.

D01D01: day 0D01: day 0D01: day 2D01: day 2D01: day 9D01: day 9D01: day 14D01: day 14D01: day 16D01: day 16D01: day 23D01: day 23D02D02: day 0D02: day 0D02: day 0D02: day 1D02: day 1D02: day 7D02: day 7D02: day 7D02: day 7D02: day 9D02: day 9D02: day 9D02: day 9D02: day 21D02: day 21D02: day 21D02: day 21D02: day 21R01R01: day 0R01: day 16R01: day 64R02R02: day 0R02: day 15R02: day 63R03R03: day 0R03: day 14R03: day 580 d16 d32 d48 d2 mo

Each row is one person (5 shown); dots are samples at days since that person's first sample.

FMT: donor D02 (16 production-stage samples) -> 3 rCDI recipients R01–R03 sampled d0/d14/d60; second donor D01 used for protocol tests.

donor: D02, R01, R02, R03D02 donor of R01D02 donor of R02D02 donor of R03D02 — donor · 18 samplesDD02R01 — recipient · 3 samplesRR01R02 — recipient · 3 samplesRR02R03 — recipient · 3 samplesRR03

donorrecipient · circles are people (pale = no sequenced sample), arrows run donor → recipient and parent → child, curved lines join twins, partners and siblings, squares are shared settings or families without recorded roles. Shown: 1 linked group from explicit relations. 5 people in the project overall.

How longitudinal and relatedness information is derived

Community composition
Faecalibacterium 11.4%CAG-267 3.8%Clostridium_A 3.7%Phil1 2.3%Bilophila 1.9%Veillonella 1.7%Pelethenecus 1.5%Ruminococcus_C 1.5%UMGS1484 1.4%Onthomonas 1.1%CAG-196 1.0%Luoshenia 0.8%not assigned to a genus 59.3%other genera 8.6%

Genera, mean relative abundance over 26 profiled gut samples of this project (Sandpiper SingleM profiles, GTDB R232; low-depth and non-metagenome profiles left out).

Field coverage
fieldsamplescoverageR1R2R3R4
age_category39 100%
country39 100%39
health_condition39 100%39
subject_id39 100%39
age_at_collection_days39 100%39
bmi39 100%39
collection_date39 100%39
detailed_location39 100%
diet39 100%39
diet_detail39 100%39
health_condition_detail39 100%39
intervention39 100%39
intervention_detail39 100%39
latitude39 100%39
location_region39 100%39
longitude39 100%39
sex39 100%39
timepoint_label9 23%9
Papers (1)
  • Engraftment of donor phageome via fecal microbiota transplantation in recurrent C. difficile infection: a prospective observational study 2025 own_data
Details
Archive description

Many attribute the 90% efficacy rate of fecal microbiota transplantation (FMT) in treating recurrent Clostridioides difficile infection (rCDi) to the restoration of the bacterial community. However, factors beyond bacteria, such as bacteriophages (phages), may also play a critical role in FMT’s success. We hence aimed to evaluate the preservation of the phage community (phageome) along the production process following Good Manufacturing Practices (GMP) at the Lausanne University Hospital (CHUV), and its engraftment in patients receiving FMT to treat rCDi. Sixteen samples, from four donations of one healthy donor, were collected at various production stages – fresh, frozen, homogenized, and encapsulated – for phageome analysis. The phage community profiles of three patients before, at 14, and 60 days after FMT were examined to evaluate donor phage engraftment. During protocol development, magnetic bead purification without further amplification yielded more viral reads and longer contigs of better quality compared to spin column purification followed by amplification. Phages were detected in all sample types, and samples clustered by donation, indicating that the pre-processing steps did not alter significantly the phage profile. The recipients’ phageome prior to FMT was characterized by low diversity, each recipient being dominated by a different phage. In contrast, the profile 14 days post-FMT demonstrated the engraftment of donor-derived phages which persisted at 60 days. Most were predicted to be temperate phages of the Caudoviricetes class infecting members of the Clostridia bacterial class, and Lachnospiraceae and Oscillospiraceae bacterial families. Our findings suggest that the CHUV production process for oral FMT capsules preserves the phage community and that donor phages successfully engraft in recipients. Further larger-scale studies and intervention trials will help elucidate the mechanisms underlying the potential of phages in FMT’s efficacy.

How this project entered the registry

Classified as human gut / stool shotgun DNA metagenome of adult by opus_adjudicated with confidence 0.70. Assay shotgun_dna.

  • host study.description · “patients receiving FMT to treat rCDi”
  • body site study.title · “fecal microbiota transplantation”
  • life stage sample.attr.host_age · “34 (n=36/39)”
Evidence examples (one per field × route)
samplefieldvaluerouteconf.sourcequote
SAMEA120321798age_at_collection_days15696.8R10.85sample.attr.host_age43
SAMEA120321798bmi20.0R10.90sample.attr.host_body_mass_index20
SAMEA120321798collection_date2021-10-12R10.90biosample.attribute:collection_date2021-10-12
SAMEA120321798countryCHR10.90sample.attr.geographic_location_country_and_or_seaSwitzerland
SAMEA120321798dietother_dietR10.90biosample.attribute:host_dietFlexitarian
SAMEA120321798diet_detailFlexitarianR10.90biosample.attribute:host_dietFlexitarian
SAMEA120321798health_conditiongi_infection_or_diarrhoeaR40.50study.titlerecurrent C. difficile infection
SAMEA120321798health_condition_detailrecurrent Clostridioides difficile infection (rCDi)R40.50study.descriptionrecurrent Clostridioides difficile infection (rCDi)
SAMEA120321798interventionno_interventionR10.90biosample.attribute:statusstatus: Donor
SAMEA120321812interventionno_interventionR10.80biosample.attribute:timepointtimepoint: d0
SAMEA120321798intervention_detailFMT stool donorR10.90biosample.attribute:statusstatus: Donor
SAMEA120321812intervention_detailbaseline sample day 0, before FMT; assigned arm: FMT recipient (timing given by timepoint key)R10.80biosample.attribute:timepointtimepoint: d0
SAMEA120321798latitude46.5260R10.90biosample.attribute:geographic_location_latitude+geographic_location_longitude46.526 6.6497
SAMEA120321798location_regionVaudR10.60biosample.attribute:geographic_location_latitude+geographic_location_longitude46.526 6.6497
SAMEA120321798longitude6.6497R10.90biosample.attribute:geographic_location_latitude+geographic_location_longitude46.526 6.6497
SAMEA120321798sexmaleR10.90sample.attr.host_sexmale
SAMEA120321798subject_idD01R10.85sample.attr.individualD01
SAMEA120321812timepoint_labeld0R10.85sample.attr.timepointd0
Sequencing

39 runs over 39 samples · mean 1.61 Gbp per run (median 1.42 Gbp, total 62.65 Gbp; 39 runs with a base count) · layout PAIRED 39 · platform ILLUMINA 39 · models NextSeq 1000 (25), Illumina MiSeq (14) · 77% of runs with a Sandpiper profile · first public 2025-10-31

Authors (0)

No author record.

Downloads

PRJEB97162.csv.gz (2.2 KB) · parquet (73.7 KB) — all 39 samples, every field with route and confidence · PRJEB97162_determinations.csv.gz (4.8 KB) — 594 evidence rows

Samples (39 · every field this project has values for · hover a cell for its source)
Loading the sample table…